Renaissance Group LLC lowered its stake in shares of HCA Healthcare, Inc. (NYSE:HCA – Get Rating) by 1.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 126,266 shares of the company’s stock after selling 1,944 shares during the quarter. Renaissance Group LLC’s holdings in HCA Healthcare were worth $32,440,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of HCA. Equitec Proprietary Markets LLC bought a new stake in HCA Healthcare during the 4th quarter worth about $26,000. Amplius Wealth Advisors LLC bought a new stake in HCA Healthcare during the 4th quarter worth about $27,000. PYA Waltman Capital LLC acquired a new position in HCA Healthcare during the 4th quarter valued at about $31,000. Ellevest Inc. lifted its position in HCA Healthcare by 1,172.7% during the 4th quarter. Ellevest Inc. now owns 140 shares of the company’s stock valued at $36,000 after purchasing an additional 129 shares during the period. Finally, Gradient Investments LLC lifted its position in HCA Healthcare by 65.3% during the 4th quarter. Gradient Investments LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 62 shares during the period. 67.87% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Kathleen M. Whalen sold 500 shares of HCA Healthcare stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $215.38, for a total transaction of $107,690.00. Following the completion of the sale, the senior vice president now owns 11,373 shares of the company’s stock, valued at $2,449,516.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Joseph A. Sowell III sold 11,522 shares of the business’s stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $269.00, for a total value of $3,099,418.00. The disclosure for this sale can be found here. Over the last three months, insiders purchased 91,370 shares of company stock valued at $19,373,375 and sold 14,380 shares valued at $3,723,203. 1.50% of the stock is currently owned by company insiders.
HCA Healthcare (NYSE:HCA – Get Rating) last released its earnings results on Friday, April 22nd. The company reported $4.12 earnings per share for the quarter, missing the consensus estimate of $4.25 by ($0.13). HCA Healthcare had a net margin of 11.40% and a return on equity of 405.72%. The firm had revenue of $14.95 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the business posted $4.14 earnings per share. HCA Healthcare’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, analysts anticipate that HCA Healthcare, Inc. will post 17.15 earnings per share for the current year.
HCA Healthcare declared that its board has initiated a share buyback plan on Thursday, January 27th that allows the company to repurchase $8.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 16th will be paid a $0.56 dividend. The ex-dividend date is Wednesday, June 15th. This represents a $2.24 annualized dividend and a dividend yield of 1.09%. HCA Healthcare’s dividend payout ratio is presently 10.54%.
A number of research analysts have issued reports on the stock. Truist Financial cut their target price on shares of HCA Healthcare from $310.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, April 25th. SVB Leerink cut their price target on shares of HCA Healthcare from $304.00 to $273.00 and set an “outperform” rating on the stock in a research report on Monday, April 25th. Raymond James cut their price target on shares of HCA Healthcare from $275.00 to $245.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 26th. TheStreet upgraded shares of HCA Healthcare from a “c+” rating to a “b-” rating in a research report on Monday, March 21st. Finally, Mizuho cut their price target on shares of HCA Healthcare from $290.00 to $260.00 in a research report on Tuesday, May 3rd. Six investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, HCA Healthcare currently has an average rating of “Buy” and an average target price of $261.38.
About HCA Healthcare (Get Rating)
HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
- Get a free copy of the StockNews.com research report on HCA Healthcare (HCA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.